Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-flexible-dose Study of Lu AF11167 for the Treatment of Persistent Prominent Negative Symptoms in Patients With Schizophrenia

NCT03793712 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT03793712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03793712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-flexible-dose Study of Lu AF11167 for the Treatment of Persistent Prominent Negative Symptoms in Patients With Schizophrenia
Lead sponsor
H. Lundbeck A/S
Phase
Phase 2
Overall status
Terminated
Start date
December 27, 2018
Completion date
September 3, 2020
Enrollment
168 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia